Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

Da­ta from a mid-stage obe­si­ty tri­al of Met­sera’s long-act­ing in­jectable GLP-1 ag­o­nist sug­gest it could be com­pet­i­tive with ap­proved in­cretins and sev­er­al in­ves­ti­ga­tion­al com­pounds. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER